GLP-1 Drugs
30 articles on GLP-1 Drugs, written by Shotlee and medically reviewed for clinical accuracy.
Christina Aguilera 'Thinner Than Ever' in Braless Dress Amid Ozempic Rumors
Christina Aguilera turned heads at the Breakthrough Prize Ceremony, appearing 'thinner than ever' in a plunging black leather dress that highlighted her minuscule waist. Amid ongoing Ozempic rumors, fans commented 'Ozempic strikes again' on her super-slim frame. This sighting reignites discussions on celebrity weight loss and GLP-1 medications.
5 min read
Inside India's GLP-1 Rush: Generics, Hype, Risks
In India, the GLP-1 rush is on—patients demand Ozempic or Mounjaro by name, generics slash costs to ₹1,290/month, fueled by Instagram and forums. But endocrinologists caution against indiscriminate use amid nausea, rebound weight, and serious risks. Inside the hype reshaping obesity treatment.
5 min read
Safely Buy GLP-1 Drugs Online: Key Facts Amid Ad Surge
Serena Williams' 2026 Super Bowl ad spotlighted her GLP-1 weight-loss journey, fueling massive online searches for drugs like Ozempic and Wegovy. With ads bombarding daily life and insurance often falling short, a booming online market offers cheaper options—but at what risk? Here's what you need to know to safely buy GLP-1 drugs online.
5 min read
Can Biopeptides Reclaim Weight Loss from GLP-1 Drugs?
As GLP-1 drugs like Ozempic transform weight loss, biotech startup Lembas argues biopeptides can reclaim a role through food-based satiety support. CEO Shay Hillel, speaking at Future Food-Tech San Francisco, positions these short proteins as complements—not replacements—for better metabolic health. With clinical trials underway, functional foods may soon enhance GLP-1 therapy.
5 min read
GLP-1 Weight-Loss Drugs Face Bone Health Risks in Older Adults
Emerging research is raising questions about GLP-1 weight-loss drugs like Ozempic and Wegovy, showing a potential link to bone loss and fractures in older adults. A major study in the Journal of Clinical Endocrinology & Metabolism found higher fragility fracture risks among seniors on these medications. Experts stress monitoring and preventive steps to balance benefits with bone protection.
5 min read
Biggest Mistake GLP-1 Users Make, Doctor Says
A surge in GLP-1 drug use has millions turning to shots like Ozempic or pills like Wegovy for weight loss, but doctors warn of a critical error. The biggest mistake? Thinking the prescription is enough without lifestyle changes. A study of 98,000 veterans shows combining GLP-1s with healthy habits slashes cardiovascular risks by 43%.
6 min read
GLP-1 Drugs Surge: Healthy Habits Still Essential for Best Results
Demand for GLP-1 drugs like Wegovy and Zepbound is booming, with 1 in 8 Americans now using them. But experts warn: medication alone isn't enough—pairing with healthy habits like protein-rich meals, exercise, and sleep amplifies weight loss and health gains, per recent studies.
6 min read
Grim Effects of Stopping GLP-1s Like Ozempic, Study Finds
New research paints a stark picture: stopping GLP-1 drugs like Ozempic can rapidly reverse cardiovascular benefits, with risks spiking 8% after just six months. Published in BMJ Medicine, the study tracked over 333,000 adults and warns of 'metabolic whiplash.' Patients face weight regain, inflammation resurgence, and lasting scars from interruptions.
4 min read
ARD-201 Trial: Maintaining Weight Loss After Ozempic, Wegovy
GLP-1 drugs like Ozempic and Wegovy deliver impressive weight loss, but regain is common after stopping. A new Phase 2 trial of oral ARD-201 aims to change that by regulating appetite via bitter taste receptors. Led by obesity expert Lawrence Cheskin at George Mason University, this study targets post-treatment weight maintenance.
5 min read
GLP-1 Drugs Boost Dairy Demand for Yogurt and Cottage Cheese
GLP-1 drugs like Ozempic and Wegovy are reshaping eating habits, slashing demand for pastries while surging sales of protein-rich yogurt and cottage cheese. Studies show users cut grocery spending by 6-9%, favoring nutrient-dense dairy. Dairy giants like Arla and Ehrmann are capitalizing with GLP-1-friendly products.
10 min read
Celeb Agent: Why Stars Hide Ozempic, Wegovy Use
When celebrities drop dress sizes fast, whispers of 'fat jabs' like Ozempic fill the air—but stars stay mum. A veteran celeb agent exposes the regulatory pitfalls, contract traps, and multimillion-dollar reasons behind the secrecy. From TV bans to brand conflicts, here's why honesty could cost them dearly.
4 min read
Should You Take GLP-1 Drugs for Longevity?
A quote from The Economist's Style Guide warns against calling anything a panacea—yet GLP-1 drugs for type 2 diabetes and obesity are now eyed by healthy individuals for longevity. Is their time as a miracle cure finally here? This guide weighs the excitement against expert caution and real-world considerations.
4 min read
Govt Cautions Pharma Cos on Surrogate Ads for GLP-1 Drugs
The Indian government has issued a strict advisory cautioning pharmaceutical companies against surrogate advertising to promote GLP-1 drugs, amid fears of consumer misuse. Signed by Drugs Controller General Rajeev Singh Raghuvanshi on March 10, the note prohibits all direct or indirect promotions on any platform. This comes as Ozempic and Wegovy patents near expiry, potentially flooding the market with generics.
6 min read
Novo, Hims End GLP-1 Feud, Partner Again on Wegovy
The months-long GLP-1 feud between Novo Nordisk and Hims & Hers Health is over, with a new partnership to sell Wegovy via Hims' telehealth platform expected Monday. Following a recent lawsuit over copycat drugs, shares surged: Hims nearly 40%, Novo 2% after-hours. Analysts call it a surprise positive for expanded market reach.
5 min read
Snack Sales Hold Steady Despite GLP-1 Weight Loss Surge, USDA Data Shows
Despite fears that surging GLP-1 weight loss drugs would slash snack sales, new USDA data shows units holding steady at over 10 billion annually through 2024. Prescriptions rose from 0.5% to 2% of adults, yet food consumption patterns surprise economists. Discover the resilience, consumer shifts, and future outlook.
6 min read
GLP-1 Drugs May Raise Osteoporosis and Gout Risk, Study Suggests
New research tracking nearly 150,000 people on GLP-1 medications like Ozempic and Wegovy suggests higher risks of osteoporosis, gout, and osteomalacia over five years. While not proving causation, the study highlights potential impacts on bone and joint health from rapid weight loss. Experts emphasize nutrition, exercise, and monitoring to mitigate risks.
5 min read
NC Poison Control Warns GLP-1 Users to Use Caution
North Carolina Poison Control is alerting GLP-1 users to watch for common dosing mistakes after averaging one to two calls daily last year. With 80% involving administration errors for drugs like Ozempic, Wegovy, and Mounjaro, most cases were mild but highlight real risks. Discover symptoms, prevention strategies, and FDA advice on compounded GLP-1 drugs.
5 min read
New Diet Lowers Methionine & Cysteine to Trigger Fat Burning Without Exercise
Lab mice shed pounds when key amino acids—methionine and cysteine—were cut from their diet, igniting fat burning without exercise. A University of Southern Denmark study shows this diet-induced thermogenesis boosted calorie burn by 20%, nearly matching constant cold exposure. This could redefine obesity treatments beyond GLP-1 drugs.
6 min read
Katy Perry's Weight Loss Journey Fuels Ozempic Rumors
Katy Perry's noticeable weight loss transformation starting in 2023 has fans speculating about Ozempic use, even as she credits diet and hydration. Online chatter about 'Ozempic face' intensified after her 2024 performances and social media posts. Despite denials from Perry and sources, rumors persist into 2025.
6 min read
Big Food Invests Millions in Rebrands as GLP-1 Drugs Reshape Demand
Global food giants like PepsiCo and Coca-Cola are ramping up investments in rebranded, protein-rich products as GLP-1 drugs suppress appetite and alter eating habits across 20% of U.S. households. With potential $12 billion in lost snack sales over the next decade, companies are shifting to smaller portions and nutrient-dense options. This adaptation highlights the lasting ripple effects of obesity medications on the food industry.
5 min read
Dentist Warns of 'Ozempic Teeth': Rapid Decay from GLP-1 Drugs
A US dentist is raising alarms about 'Ozempic teeth,' a term for rapid tooth decay and gum issues in GLP-1 users. Dr. Gerry Curatola links it to slowed gastric emptying, bile flow, dry mouth, and vitamin deficiencies. While the drugs aid weight loss, awareness and simple prevention steps are key to avoiding dental pitfalls.
6 min read
Semaglutide: Artificial Shortage as Novo Nordisk's Business Model?
Novo Nordisk's lawsuit against Hims & Hers claims compounded semaglutide sales are illegal now that shortages ended. But is this about patient safety or enforcing high prices like $150/month for Wegovy pills versus $50 alternatives? Dive into how patents create artificial semaglutide shortages.
5 min read
McDonald's Execs Plan for More GLP-1 Customers Like Ozempic Users
McDonald's executives revealed plans to cater to the growing number of customers on GLP-1 drugs like Ozempic during their latest earnings call. With users seeking high-protein options and avoiding sugary drinks, the chain is testing menu tweaks. This shift reflects broader changes in the food industry as GLP-1 adoption hits 10% of the US population.
6 min read
GLP-1 Drugs May Cut Airline Fuel Costs by $580M
GLP-1 weight loss drugs like Ozempic may trim airline fuel bills alongside waistlines. A Jefferies report estimates $580M annual savings for top US carriers from lighter passengers. Discover the science and implications.
2 min read
Obesity Medications: How They Might Transform the GLP-1 Sector
The GLP-1 market, initially dominated by weekly injections, is entering a new phase with the introduction of obesity pills. These oral options from Novo Nordisk and Eli Lilly promise greater convenience and possibly lower costs, attracting new users and reshaping the industry. Analysts predict significant market growth, with pills capturing a substantial share by 2030.
9 min read
2026 Signals the Era of Obesity Pills: Uncovering Their Role in Transforming the GLP-1 Market
The year 2026 heralds a shift in obesity treatment with the arrival of GLP-1 pills from Novo Nordisk and Eli Lilly, offering potential alternatives to injections. These oral options promise greater convenience and affordability, possibly attracting new patients to weight loss therapies. Experts highlight their role in expanding the market while maintaining similar efficacy.
2 min read
6 Facts to Understand About the New GLP-1 Weight Loss Pill
The introduction of a GLP-1 pill for weight loss marks a significant advancement in obesity treatment, offering an oral alternative to injections like Wegovy. Experts highlight its potential for broader access, though it shares similar expenses, adverse effects, and the necessity for a healthy lifestyle. Key details cover efficacy, timelines for results, pricing, side effects, dosing requirements, and upcoming options.
4 min read
Key Insights on Weight Loss Medications for 2026
Weight loss medications such as Wegovy and Zepbound are set to become more accessible and affordable, moving beyond high costs and weekly shots. New pill forms offer alternatives for those avoiding injections, with significant developments in GLP-1 treatments expected. Advances in pricing and access programs aim to broaden availability for patients.
6 min read
A GLP-1 Weight Loss Pill Approaches. Here's Its Comparison to Injections
Injectable GLP-1 medications have revolutionized obesity management, and now an oral option is emerging. The FDA has approved a pill version of semaglutide for weight loss and cardiovascular risk reduction.
1 min read
Jonathan Van Ness from Queer Eye Reveals Ab Selfie Post GLP-1 Weight Reduction
Jonathan Van Ness has candidly shared about his weight loss experience, shedding nearly 70 pounds using GLP-1 drugs while addressing body positivity concerns. He emphasizes feeling better through medication and Pilates. Health tracking apps like Shotlee can help monitor such progress.
2 min read